Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca AbfiledCriticalAstrazeneca Ab
Priority to CU20100003ApriorityCriticalpatent/CU20100003A7/en
Publication of CU20100003A7publicationCriticalpatent/CU20100003A7/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Un compuesto de fórmula (I) ESPACIO PARA LA FÓRMULA o una sal farmacéuticamente aceptable del mismo, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia, por ejemplo en el tratamiento de una enfermedad proliferativa tal como cáncer y particularmente en una enfermedad mediada por una mTOR quinasa y/o una o más enzimas PI3K.A compound of formula (I) SPACE FOR FORMULA or a pharmaceutically acceptable salt thereof, processes for its preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of a proliferative disease such as cancer and particularly in a disease mediated by an mTOR kinase and / or one or more PI3K enzymes.
CU20100003A2010-01-082010-01-08
PIRIMIDINE TRISUSTITUTE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES
CU20100003A7
(en)
Tricyclic compounds that inhibit the kinase pi3 (pi3k); pharmaceutical composition that includes them; method to treat cancer; and its use for the treatment of cancer.
DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES